Agilent Technologies (NYSE:A – Get Rating) had its target price reduced by SVB Securities from $170.00 to $145.00 in a research note issued to investors on Wednesday, The Fly reports. SVB Securities currently has an outperform rating on the medical research company’s stock.
Several other brokerages also recently weighed in on A. Robert W. Baird decreased their target price on Agilent Technologies from $174.00 to $144.00 and set an outperform rating for the company in a research report on Wednesday. Evercore ISI decreased their target price on Agilent Technologies from $150.00 to $126.00 and set an outperform rating for the company in a research report on Wednesday. StockNews.com initiated coverage on Agilent Technologies in a research note on Thursday, May 18th. They issued a buy rating on the stock. Wells Fargo & Company cut their price target on Agilent Technologies from $170.00 to $160.00 and set an overweight rating on the stock in a research note on Wednesday. Finally, Citigroup cut their price target on Agilent Technologies from $150.00 to $130.00 and set a neutral rating on the stock in a research note on Wednesday. Three investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat, Agilent Technologies has an average rating of Moderate Buy and an average price target of $151.35.
Agilent Technologies Price Performance
Shares of Agilent Technologies stock opened at $120.99 on Wednesday. Agilent Technologies has a twelve month low of $112.52 and a twelve month high of $160.26. The stock has a market capitalization of $35.78 billion, a P/E ratio of 27.31, a PEG ratio of 1.89 and a beta of 1.03. The company has a current ratio of 2.11, a quick ratio of 1.53 and a debt-to-equity ratio of 0.49. The business’s fifty day moving average price is $133.87 and its 200 day moving average price is $144.11.
Agilent Technologies Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Wednesday, July 26th. Shareholders of record on Monday, July 3rd will be given a dividend of $0.225 per share. The ex-dividend date is Friday, June 30th. This represents a $0.90 dividend on an annualized basis and a yield of 0.74%. Agilent Technologies’s dividend payout ratio (DPR) is presently 20.32%.
Institutional Trading of Agilent Technologies
Hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Inc. lifted its stake in Agilent Technologies by 1.9% during the third quarter. BlackRock Inc. now owns 32,943,190 shares of the medical research company’s stock valued at $4,004,242,000 after purchasing an additional 629,153 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Agilent Technologies by 1.0% during the 3rd quarter. Vanguard Group Inc. now owns 24,955,720 shares of the medical research company’s stock worth $3,033,368,000 after acquiring an additional 257,455 shares in the last quarter. State Street Corp grew its holdings in shares of Agilent Technologies by 0.6% in the 3rd quarter. State Street Corp now owns 13,152,295 shares of the medical research company’s stock worth $1,598,661,000 after acquiring an additional 73,495 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in shares of Agilent Technologies by 6.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 8,218,926 shares of the medical research company’s stock valued at $1,137,008,000 after purchasing an additional 511,874 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA boosted its position in shares of Agilent Technologies by 10.7% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 6,478,670 shares of the medical research company’s stock valued at $787,483,000 after purchasing an additional 627,517 shares during the period.
About Agilent Technologies
Agilent Technologies, Inc engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers application-focused solutions that include instruments and software that identify, quantify, and analyze the physical and biological properties of substances and products, as well as the clinical and life sciences research areas to interrogate samples at the molecular and cellular level.
- Get a free copy of the StockNews.com research report on Agilent Technologies (A)
- Toll Brothers Rises On Results, But The Roof Is In Place
- It’s Time To Try On VF Corporation’s 6% Yield
- PetCo Management Getting it Right? Earnings Beat Says Yes
- Axcelis Stock In Buy Range After Chart Breakout, Strong Guidance
- Kohl’s 10% Yield Comes Into High Fashion
Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.